Published in Oncogene on September 25, 2006
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol (2010) 5.35
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer (2011) 3.85
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci U S A (2008) 1.97
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol (2013) 1.55
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol (2010) 1.44
The role of BRD7 in embryo development and glucose metabolism. J Cell Mol Med (2016) 1.38
Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discov (2013) 1.32
Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat (2011) 1.31
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA (2015) 1.26
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci U S A (2008) 1.25
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov (2012) 1.25
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 1.24
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma (2008) 1.18
Loss of DNA polymerase zeta enhances spontaneous tumorigenesis. Cancer Res (2010) 1.15
The role of BRCA1 in DNA damage response. Protein Cell (2010) 1.14
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J Cell Biol (2013) 1.12
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res (2011) 1.11
HES1 is a novel interactor of the Fanconi anemia core complex. Blood (2008) 1.10
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat (2009) 1.10
BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 sub-genotypes: explanation for the "BRCA paradox"? PLoS One (2012) 1.07
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer (2010) 1.06
Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models. Dis Model Mech (2013) 1.05
Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci (2011) 1.05
Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. EBioMedicine (2015) 1.04
Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.03
Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer (2008) 1.00
DNA double-strand break signaling and human disorders. Genome Integr (2010) 1.00
A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1. PLoS One (2012) 0.96
Preclinical mouse models for BRCA1-associated breast cancer. Br J Cancer (2009) 0.95
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer (2008) 0.93
Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat (2013) 0.92
Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J (2016) 0.92
brca2 in zebrafish ovarian development, spermatogenesis, and tumorigenesis. Proc Natl Acad Sci U S A (2010) 0.91
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2009) 0.90
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proc Natl Acad Sci U S A (2013) 0.89
EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics (2011) 0.89
Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes. PLoS Genet (2011) 0.86
New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol (2007) 0.86
Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol (2011) 0.85
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis. Neoplasia (2008) 0.84
Analysis of induced pluripotent stem cells from a BRCA1 mutant family. Stem Cell Reports (2013) 0.83
RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene (2015) 0.81
Absence of BRCA/FMR1 correlations in women with ovarian cancers. PLoS One (2014) 0.80
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas. BMC Cancer (2015) 0.80
Recent advances in breast cancer genetics. Cancer Treat Res (2008) 0.80
Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications. Cancer Res (2008) 0.79
The two faces of DNA repair: disease and therapy. Mo Med (2013) 0.78
Loss of GGN leads to pre-implantation embryonic lethality and compromised male meiotic DNA double strand break repair in the mouse. PLoS One (2013) 0.78
When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans. Hered Cancer Clin Pract (2016) 0.77
Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77
GI GEMs: genetically engineered mouse models of gastrointestinal disease. Gastroenterology (2010) 0.77
53BP1 ablation rescues genomic instability in mice expressing 'RING-less' BRCA1. EMBO Rep (2016) 0.76
The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis. Cell Cycle (2016) 0.76
Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells. Proc Natl Acad Sci U S A (2015) 0.76
RANKL/RANK: from bone loss to the prevention of breast cancer. Open Biol (2016) 0.75
Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function. Cell Rep (2017) 0.75
Engineered Swine Models of Cancer. Front Genet (2016) 0.75
Brca2 deficiency leads to T cell loss and immune dysfunction. Mol Cells (2015) 0.75
Fanconi anemia signaling and Mus81 cooperate to safeguard development and crosslink repair. Nucleic Acids Res (2014) 0.75
Mouse models of inherited cancer syndromes. Hematol Oncol Clin North Am (2010) 0.75
Modeling the study of DNA damage responses in mice. Methods Mol Biol (2015) 0.75
ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci U S A (2017) 0.75
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev (2000) 5.71
Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A (2001) 4.51
A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep (2001) 3.67
Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J (1999) 3.18
Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice. J Virol (1997) 1.66
Mouse model systems to study multistep tumorigenesis. Cold Spring Harb Symp Quant Biol (1994) 1.06
Preclinical mouse models for BRCA1-associated breast cancer. Br J Cancer (2009) 0.95
Identification and characterization of collaborating oncogenes in compound mutant mice. Cancer Res (1999) 0.94
Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther (2000) 0.89
Mouse models for sporadic cancer. Exp Cell Res (2001) 0.86
Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene (2009) 0.85
The effect of process conditions on the alpha-amylolytic hydrolysis of amylopectin potato starch: An experimental design approach. Biotechnol Bioeng (1999) 0.75